XLXiaodong Luo

Xiaodong Luo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Xiaodong Luo has a total of 54 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Multiplicity Control in Clinical Trials with Adaptive Selection Followed by Group-Sequential Testing

    by Kaiyuan Hua, Xiaofei Wang, Xiaodong Luo

    1 IntroductionClinical trials often have multiple objectives for different endpoints, populations, and treatment groups (Bauer, 1991; Bender & Lange, 2001; Chow & Chang, 2008; FDA, 2017). Without e...


  • Open Access

    Phase 1 Trials of Gatralimab, a Next-Generation Humanized Anti-CD52 Monoclonal Antibody, in Participants with Progressive Multiple Sclerosis

    by Fredrik N. Albach, Christian Geier, Christian Keicher, Maximilian G. Posch, Stephan J. Schreiber, Gerald Grütz, Levent Akyüz, Xiaodong Luo, Annaig Le-Halpere, Philippe Truffinet, et al.

    Introduction Lymphocyte depletion via anti-CD52 monoclonal antibody (mAb) therapy is an effective treatment strategy for relapsing–remitting multiple sclerosis (MS) but is associated with infusion/injection-associated reactions (IARs) and autoimmune-related adverse events (AEs). Gatralimab is a next-generation humanized anti-CD52 mAb. Methods Two first-in-human trials were conducted in participants with progressive MS to assess the pharmacodynamics, pharmacokinetics, and safety of gatralimab administered via subcutaneous (SC) and intravenous (IV) routes, and to determine the effect of different comedication regimes on IARs to SC gatralimab. A Phase 1 trial (NCT02282826) included double-blind, placebo-controlled sequential ascending single IV (1, 3.5, and 12 mg) and SC (12, 36, and 60 mg) dose groups. A Phase 1b trial (NCT02977533) involved five groups who received SC gatralimab (36, 48, or 60 mg) and different comedications. A long-term safety (LTS) study (NCT02313285) examined safety and pharmacodynamics over 4 years. Results Gatralimab produced depletion of lymphocytes (dose-dependently) and CD4+ regulatory T cells, with partial repopulation to normal values by approximately 12 months. Peak serum gatralimab concentrations followed dose-proportionality and were delayed by 6.0–7.5 days following SC administration. Treatment-emergent AEs, including IARs, were reported for most participants but were generally of mild or moderate severity, and treatment-emergent serious AEs were mostly MS-related. Methylprednisolone and antihistamine comedications were associated with reduced incidence of fevers and skin and subcutaneous tissue AEs, respectively. During the LTS study, one participant (3.0%) experienced an autoimmune-related AE (Basedow’s disease), and subsequently died from pulmonary sepsis deemed unrelated to gatralimab by the investigator. Conclusions These data show that gatralimab achieves the desired pharmacodynamic effect of lymphocyte depletion followed by repopulation, and has an acceptable safety profile, including low risk of non-MS autoimmunity. Although gatralimab is no longer in development for MS, insights from these trials may inform the development of comedication regimes of future anti-CD52 mAbs and subcutaneous formulations of other lymphocyte-depleting mAbs. Trial registration NCT02282826, NCT02977533, NCT02313285.


  • Open Access

    An innovative phase 2 proof‐of‐concept trial design to evaluate SAR445088, a monoclonal antibody targeting complement C1s in chronic inflammatory demyelinating polyneuropathy

    by Luis Querol, Richard A. Lewis, Hans‐Peter Hartung, Pieter A. Van Doorn, Erik Wallstroem, Xiaodong Luo, Miguel Alonso‐Alonso, Nazem Atassi, Richard A. C. Hughes

    Background and Aims: Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare immune‐mediated disease of the peripheral nerves, with significant unmet treatment needs. Clinical trials in CIDP are challenging; thus, new trial designs are needed. We present design of an open‐label phase 2 study (NCT04658472) evaluating efficacy and safety of SAR445088, a monoclonal antibody targeting complement C1s, in CIDP.Methods: This phase 2, proof‐of‐concept, multicenter, open‐label trial will evaluate the efficacy, and safety of SAR445088 in 90 patients with CIDP across three groups: (1) currently treated with standard‐of‐care (SOC) therapies, including immunoglobulin or corticosteroids (SOC‐Treated); (2) refractory to SOC (SOC‐Refractory); and (3) naïve to SOC (SOC‐Naïve). Enrolled participants undergo a 24‐week treatment period (part A), followed by an optional treatment extension for up to an additional 52 weeks (part B).In part A, the primary endpoint for the SOC‐Treated group is the percentage of participants with a relapse after switching from SOC to SAR445088. The primary endpoint for the SOC‐Refractory and SOC‐Naïve groups is the percentage of participants with a response, compared to baseline. Secondary endpoints include safety, tolerability, immunogenicity, and efficacy of SAR445088 during 12‐week overlapping period (SOC‐Treated). Part B evaluates long‐term safety and durability of efficacy. Data analysis will be performed using Bayesian statistics (predefined efficacy thresholds) and historical data‐based placebo assumptions to support program decision‐making.Interpretation: This innovative trial design based on patient groups and Bayesian statistics provides an efficient paradigm to evaluate new treatment candidates across the CIDP spectrum and can help accelerate development of new therapies.


  • Some Multiplicity Adjustment Procedures for Clinical Trials with Sequential Design and Multiple Endpoints

    by Xiaodong Luo, Hui Quan

    This paper proposes some new multiplicity adjustment procedures for clinical trials with multiple endpoints and multiple interim analyses. The proposed sequential procedures, adapting the popular multiple comparison procedures for fixed time-point design and utilizing α-spending for each endpoint, are shown to strongly control the family-wise type-1 error rate and provide powerful yet versatile multiplicity adjustment solutions for monitoring multiple endpoints via interim analyses.


  • Open Access

    A hybrid SVR with the firefly algorithm enhanced by a logarithmic spiral for electric load forecasting

    by Weiguo Zhang, Linlin Gu, Yang Shi, Xiaodong Luo, Hu Zhou

    Accurate forecasting of an electric load is vital in the effective management of a power system, especially in flourishing regions. A new hybrid model called logarithmic spiral firefly algorithm-support vector regression (LS-FA-SVR) is proposed to promote the performance of electric load forecasting. The new hybrid model is acquired by combining the support vector regression, firefly algorithm, and logarithmic spiral. Half-hourly electric load from five main regions (NSW, QLD, SA, TAS, and VIC) of Australia are used to train and test the proposed model. By comparing the model results with observed data on the basis of the root mean squared error (RMSE), mean absolute error (MAE), and mean absolute percent error (MAPE), the performance of the proposed hybrid model is the most outstanding among all the considered benchmark models. Hence, the results of this study show that the hybrid model LS-FA-SVR is preferable and can be applied successfully because of its high accuracy.


  • A MCP‐Mod approach to designing and analyzing survival trials with potential non‐proportional hazards

    by Xiaodong Luo, Yuan Sun, Zhixing Xu

    Non‐proportional hazards have been observed in many studies especially in immuno‐oncology clinical trials. Traditional analysis using the combined approach with log‐rank test as the significance test and Cox model for treatment effect estimation becomes questionable as this approach relies heavily on the proportional hazards assumption. Inspired by the MCP‐Mod (multiple comparisons and modeling approach) that has been widely used in dose‐finding studies, we propose a similar approach to handle non‐proportional hazards. Using this approach, efficacy signal is first established by a max‐combo test, after which hazard ratios across time will be estimated using a logically nested splines model. Simulations studies and real‐data examples are used to illustrate the use of this approach.


  • Bayesian methods for the analysis of early‐phase oncology basket trials with information borrowing across cancer types

    by Jin Jin, Marie‐Karelle Riviere, Xiaodong Luo, Yingwen Dong

    Research in oncology has changed the focus from histological properties of tumors in a specific organ to a specific genomic aberration potentially shared by multiple cancer types. This motivates the basket trial, which assesses the efficacy of treatment simultaneously on multiple cancer types that have a common aberration. Although the assumption of homogeneous treatment effects seems reasonable given the shared aberration, in reality, the treatment effect may vary by cancer type, and potentially only a subgroup of the cancer types respond to the treatment. Various approaches have been proposed to increase the trial power by borrowing information across cancer types, which, however, tend to inflate the type I error rate. In this article, we review some representative Bayesian information borrowing methods for the analysis of early‐phase basket trials. We then propose a novel method called the Bayesian hierarchical model with a correlated prior (CBHM), which conducts more flexible borrowing across cancer types according to sample similarity. We did simulation studies to compare CBHM with independent analysis and three information borrowing approaches: the conventional Bayesian hierarchical model, the EXNEX approach, and Liu's two‐stage approach. Simulation results show that all information borrowing approaches substantially improve the power of independent analysis if a large proportion of the cancer types truly respond to the treatment. Our proposed CBHM approach shows an advantage over the existing information borrowing approaches, with a power similar to that of EXNEX or Liu's approach, but the potential to provide substantially better control of type I error rate.


  • Analysis of Response Data for Assessing Treatment Effects in Comparative Clinical Studies

    by Bo Huang, Lu Tian, Zachary R. McCaw, Xiaodong Luo, Enayet Talukder, Mace Rothenberg, Wanling Xie, Toni K. Choueiri, Dae Hyun Kim, Lee-Jen Wei

    This article describes a method for estimating treatment effects, the probability-of-being-in-response curve, which can be used to visualize how rapidly patients respond to therapy and how long the... In comparative studies, treatment effect is often assessed using a binary outcome that indicates response to the therapy. Commonly used summary measures for response include the cumulative and curr...